STOCK TITAN
  1. Home
  2. News
  3. EVO

Evotec SE - EVO STOCK NEWS

Welcome to our dedicated news page for Evotec SE (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec SE.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evotec SE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evotec SE's position in the market.

News
Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth
Rhea-AI Summary
Evotec reported financial results for fiscal year 2023, meeting updated guidance. The company announced a priority reset to focus on profitable growth, with adjustments expected to drive annualized EBITDA improvement over €40 million. Despite challenges, group revenues increased by 4% to €781.4 million, with Just - Evotec Biologics revenue up 111%. Adjusted Group EBITDA was €66.4 million. Strategic partnerships with Bristol Myers Squibb and Janssen, new collaborations, CEO transition, and approval of targets by SBTi were highlighted. Evotec plans to update mid-term forecast with H1 2024 results, expecting double-digit revenue growth and reduction in unpartnered R&D expenses. The company aims for sustainable and profitable growth, with a priority reset to streamline operations and enhance profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.63%
Tags
earnings
-
News
Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
Rhea-AI Summary
Evotec SE appoints Dr. Christian Wojczewski as the new Chief Executive Officer, effective July 1, 2024. Dr. Wojczewski brings over 20 years of experience in management positions, most recently as CEO of Mediq and at Linde Healthcare. The appointment follows an extensive selection process. The current Interim CEO, Dr. Mario Polywka, will retire at the end of June.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.94%
Tags
management
-
News
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS
Rhea-AI Summary
Evotec SE and Variant Bio, Inc. have entered into a strategic partnership to discover and develop treatments for fibrotic diseases. The collaboration combines Variant Bio's genomic discovery platform with Evotec's R&D expertise to address unmet medical needs in fibrotic indications. The agreement includes research funding, milestones, and royalty payments to Evotec based on program success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
partnership
News
Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024
Rhea-AI Summary
Evotec SE will announce its financial results for 2023 on April 24, 2024, and hold a conference call to discuss the results and provide an update on its performance. The conference call will be held in English at 3.00 pm CEST. Webcast and phone details are provided for participation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
earnings
-
News
Evotec welcomes Aurélie Dalbiez as Chief People Officer
Rhea-AI Summary
Evotec appoints Aurélie Dalbiez as Chief People Officer, emphasizing a focus on people strategy, culture, and employee engagement. With over 25 years of HR leadership experience, Aurélie's role highlights Evotec's commitment to investing in its workforce and creating an inclusive work environment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
none
-
News
Evotec And Claris Ventures Streamline Access to Accelerate Programmes from Claris's Portfolio Companies into The Clinic
Rhea-AI Summary
Evotec SE and Claris Ventures announce an acceleration framework to streamline programs from Claris's portfolio companies into the clinic. Evotec's integrated platform will provide full range of pre-clinical and clinical development and manufacturing capabilities to Claris's biotech companies. The successful collaboration between Evotec and Claris's portfolio company IAMA Therapeutics has led to an agreement that will benefit other portfolio companies as well.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
none
News
Just - Evotec Biologics Expands Development and Manufacturing Agreement with ABL for Broadly Neutralising Antibodies Against HIV
Rhea-AI Summary
Evotec SE's subsidiary, Just - Evotec Biologics, has expanded its relationship with Advanced BioScience Laboratories, Inc. to develop a third broadly neutralising antibody (bNAb) against HIV. The collaboration aims to provide large-scale cGMP manufacturing campaigns for the bNAb and a previously developed bNAb for a Phase I clinical study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
none
-
News
Evotec SE: Invitation to Conference Call
Rhea-AI Summary
Evotec SE is holding a conference call to provide a business update and a statement on its commitment to corporate governance standards. The call will feature the Chairwoman of Evotec's Supervisory Board, Prof. Iris Löw-Friedrich, and CEO Dr. Mario Polywka, discussing the company's strategy, recent market developments, and unchanged views on Guidance 2023 and the 2025 outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.99%
Tags
none
-
News
Evotec and Crohn's & Colitis Foundation Enter Agreement to Advance Drug Discovery for Novel IBD Therapies
Rhea-AI Summary
Evotec SE (EVT) collaborates with the Crohn's & Colitis Foundation's IBD Therapeutics Incubator to advance drug discovery for inflammatory bowel disease (IBD). The collaboration focuses on developing innovative drug targets addressing fibrosis and impaired intestinal barrier function. Evotec's end-to-end integrated R&D platform will be utilized to translate groundbreaking basic research into medical innovations for IBD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
none
News
Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
Rhea-AI Summary
Evotec SE (EVT) announced a scientific achievement in its strategic partnership with Bristol Myers Squibb, resulting in a US$ 25 million payment to further research the joint neuroscience pipeline. The collaboration aims to develop disease-modifying treatments for neurodegenerative diseases, with a successful Phase I study leading to a Phase II study for BMS-986419 scheduled to commence in 2024. Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, expressed confidence in delivering new therapeutic options for patients affected by neurological disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
partnership
Stock EVO logo
Evotec SE

OTC:EVO

EVO Rankings

#1969 Ranked by Market Cap
#2965 Ranked by Stock Gains
N/A Ranked by Dividends

EVO Stock Data

2.60B
145.80M
1.61%
0.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Hamburg

About EVO

Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists.